These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20347159)

  • 1. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
    Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
    J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
    Zilkha-Falb R; Gurevich M; Hayardeny L; Achiron A
    J Neuroimmunol; 2015 Jun; 283():11-6. PubMed ID: 26004150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
    Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
    J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis.
    Smolders J; Thewissen M; Theunissen R; Peelen E; Knippenberg S; Menheere P; Cohen Tervaert JW; Hupperts R; Damoiseaux J
    J Neuroimmunol; 2011 Jun; 235(1-2):91-7. PubMed ID: 21507492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
    Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
    Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
    Yamaguchi KD; Ruderman DL; Croze E; Wagner TC; Velichko S; Reder AT; Salamon H
    J Neuroimmunol; 2008 Mar; 195(1-2):116-20. PubMed ID: 18279974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells.
    Iglesias AH; Camelo S; Hwang D; Villanueva R; Stephanopoulos G; Dangond F
    J Neuroimmunol; 2004 May; 150(1-2):163-77. PubMed ID: 15081262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J
    Expert Opin Investig Drugs; 2009 Jul; 18(7):985-9. PubMed ID: 19527103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with relapsing-remitting multiple sclerosis.
    Bilińska M; Frydecka I; Podemski R; Teodorowska R; Gruszka E
    Med Sci Monit; 2001; 7(2):251-5. PubMed ID: 11257731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
    Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M
    J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment.
    Frisullo G; Iorio R; Plantone D; Marti A; Nociti V; Patanella AK; Batocchi AP
    Mult Scler; 2011 May; 17(5):556-66. PubMed ID: 21177324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways.
    Achiron A; Gurevich M
    J Neurol Sci; 2009 Nov; 286(1-2):47-53. PubMed ID: 19596127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
    Tselis A
    Curr Opin Investig Drugs; 2010 May; 11(5):577-85. PubMed ID: 20419604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
    Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients.
    Infante-Duarte C; Weber A; Krätzschmar J; Prozorovski T; Pikol S; Hamann I; Bellmann-Strobl J; Aktas O; Dörr J; Wuerfel J; Stürzebecher CS; Zipp F
    FASEB J; 2005 Nov; 19(13):1902-4. PubMed ID: 16144955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the mechanism of laquinimod action.
    Brück W; Wegner C
    J Neurol Sci; 2011 Jul; 306(1-2):173-9. PubMed ID: 21429524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
    Harrer A; Wipfler P; Einhaeupl M; Pilz G; Oppermann K; Hitzl W; Afazel S; Haschke-Becher E; Strasser P; Trinka E; Kraus J
    J Neuroimmunol; 2011 May; 234(1-2):148-54. PubMed ID: 21450349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of season on cytokine expression in multiple sclerosis and healthy subjects.
    Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H
    J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.